Bristol-Myers Squibb Company vs ACADIA Pharmaceuticals Inc.: Examining Key Revenue Metrics

Revenue Growth: Bristol-Myers vs. ACADIA, 2014-2023

__timestamp	ACADIA Pharmaceuticals Inc.	Bristol-Myers Squibb Company
Wednesday, January 1, 2014	120000	15879000000
Thursday, January 1, 2015	61000	16560000000
Friday, January 1, 2016	17331000	19427000000
Sunday, January 1, 2017	124901000	20776000000
Monday, January 1, 2018	223807000	22561000000
Tuesday, January 1, 2019	339076000	26145000000
Wednesday, January 1, 2020	441755000	42518000000
Friday, January 1, 2021	484145000	46385000000
Saturday, January 1, 2022	517235000	46159000000
Sunday, January 1, 2023	726437000	45006000000
Monday, January 1, 2024		48300000000

Cracking the code

A Tale of Two Pharmaceutical Giants: Revenue Trends from 2014 to 2023

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success and market influence. This analysis delves into the revenue trajectories of two prominent players: Bristol-Myers Squibb Company and ACADIA Pharmaceuticals Inc., from 2014 to 2023.

Bristol-Myers Squibb, a titan in the industry, showcased a robust revenue growth, peaking at approximately $46 billion in 2021, a remarkable 192% increase from 2014. This growth underscores their strategic advancements and market penetration. In contrast, ACADIA Pharmaceuticals, a smaller yet dynamic entity, experienced a staggering 6,053% revenue surge, reaching $726 million in 2023 from a modest $120,000 in 2014.

These trends highlight the diverse growth strategies and market positions of these companies, offering valuable insights into the competitive landscape of the pharmaceutical sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025